Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view

open access
 Published online 2015 Nov 18
 

  Three separate questions can be raised to address the variety of approach: firstly, the choice of both risk-reducing surgies in patients with BRCA 1 / 2 mutation, secondly the optimal timing in performing surgical strategies and lastly the cost-effectiveness of prophylactic surgery.

 In conclusion, the management in BRCA 1 / 2 mutation carriers should be considered paramount and prevention strategies will be a dynamic area of research programs. The decision about prophylactic interventions remains highly personal, driven by women priorities. However the weight of the evidence suggests that the performance of both risk reduction surgeries could be a valid option to discuss with full knowledge of the facts.